New test aims to personalize breast cancer care before the first cut
NCT ID NCT03749421
Summary
This study is testing a genomic test called Prosigna to see if it helps doctors and patients choose the best personalized treatment before breast cancer surgery. Researchers will give the test to 60 women with hormone-positive, HER2-negative breast cancer to see if the results change their doctor's treatment plan. The goal is to learn if this test, used before surgery, can lead to more confident and effective treatment decisions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.